Ways2Capital : Jubilant Life Sciences Subsidiary To Acquire Speciality Business In US

A global pharmaceutical and life sciences company, Jubilant Life Sciences, announced that its US subsidiary, Jubilant Pharma will negotiate a possible acquisition of a speciality business in the US.

The possible acquisition will depend on due diligence, satisfactory agreements and final approval of Jubilant Life Sciences.

The proposed acquisition is likely to help the Company to position itself as a competent player in the industry.

Jubilant Life Sciences is trading in positive territory, outperforming the BSE Healthcare index and other pharma giants.

Divi’s Laboratories is dragging the Healthcare index down, and is the top loser in the index. The stock is trading lower by 18% at Rs 643 per share, after receiving import alert from USFDA.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.